王敏

    【摘要】目的：探讨曲美他嗪与酒石酸美托洛尔联合治疗风湿性心脏病合并慢性心力衰竭的临床疗效。方法：纳入2019年7月—2021年5月我院76例风湿性心脏病合并慢性心力衰竭患者，依据随机对照原则分成两组，常规组采用强心、利尿、扩血管、改善微循环治疗；在此基础上，干预组采用曲美他嗪60mg联合美托洛尔6.25～25mg口服，2周为一疗程，共2个疗程。比较两组患者临床疗效、左室收缩末内径(LVESD)、左心射血分数(LVEF)。结果：常规组有效率73.68%低于干预组92.11%，有统计学意义(P<0.05)。治疗后常规组和干预组LVESD分别为(37.12±6.82)mm、(32.09±6.37)mm，LVEF分别为(43.38±7.13)%、(49.85±7.35)%，血sFas分别为(46.89±14.57)ng/mL、(35.61±12.59)ng/mL，差有统计学意义(P<0.05)。两组不良反应分析，无统计学意义(P>0.05)。结论：曲美他嗪联合酒石酸美托洛尔对风湿性心脏病合并慢性心力衰竭的临床疗效确切，有助于改善心功能，且患者可以耐受，值得推广。

    【关键词】曲美他嗪；酒石酸美托洛尔；风湿性心脏病；慢性心力衰竭

    Clinical efficacy of trimetazidine combined with metoprolol tartrate in the treatment of rheumatic heart disease with chronic heart failure

    WANG Min

    General Department of Xianxia Street Community Health Service Center， Shanghai 200336， China

    【Abstract】Objective： To investigate the clinical efficacy of trimetazidine combined with metoprolol tartrate in the treatment of rheumatic heart disease with chronic heart failure. Methods： 76 patients with rheumatic heart disease complicated with chronic heart failure in our hospital from July 2019 to May 2021 were randomly divided into two groups ......